Biosimilars

July 30, 2020

Advocates say a number of regulatory changes could help bring more of these products on to the market.

July 24, 2020

Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.

July 09, 2020

Vote in May made FDA-approved biosimilars an "appropriate substitution" for brand-name biologics in NCCN guidelines.

July 08, 2020

Along with the other Humira biosimilars, Hulio will not be on the market till 2023.

July 06, 2020

Pacific Research Institute’s Winegarden Sees Dose of Competition as Way to Lower OOP Costs

July 02, 2020

Cardinal Health recently conducted a survey of more than 100 rheumatologists asking their feelings about biosimilars, and the findings revealed that the majority of them were familiar with and comfortable prescribing biosimilars. 

June 04, 2020

Proving therapeutic equivalence is a major hurdle.

June 04, 2020

Developing a biosimilar can be more challenging than developing the innovator product because of the need to match the attributes of a highly complex molecules.

May 18, 2020

The purpose of biosimilar is simple: reduce healthcare costs, pure and simple. Here are 11 trends affecting biosimilars over the last year in the U.S.

May 18, 2020

Just as we’ve seen the entire healthcare landscape change in 2020 because of  COVID-19, the world of biosimilars is ever-changing.